NASDAQ · Biotechnology · USD
Pasithea Therapeutics Corp. (KTTA) Stock Analysis
Pasithea Therapeutics Corp. (KTTA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
KTTA Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.42
- Previous Close
- $0.41
- Day's Range
- 0.42–0.50
- 52-Week Range
- 0.28–2.06
- Volume
- 774.92K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.34
Valuation
- Market Cap
- $16.30M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.59
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$20.43M
- Shares Outstanding
- 33.41M
- 1-Year Return
- −35.98%
Dividend and dates
- Avg Volume
- 195.76K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, KTTA closed at $0.49, −35.98% over 1 year.
Pasithea Therapeutics Corp. (KTTA) has a market capitalization of $16.30M.
In fiscal 2025, KTTA reported revenue of $0.00.
KTTA Stock Return by Calendar Year
Pasithea Therapeutics Corp. (KTTA) return since Sep 2021: what $10,000 became
- 1 year
- $10,000 $6,402
- −35.98%
- 5 years
- $10,000 $91
- −99.09%
- Since Sep 2021
- $10,000 $69
- −99.31%
If you had invested $10,000 in Pasithea Therapeutics Corp. (KTTA) at the close on September 15, 2021, the earliest close on record here, it would have been worth $69 at the close on October 21, 2026: −99.31% in total, −62.38% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −62.19% |
| 2025 | −59.05% |
| 2024 | −57.43% |
| 2023 | −42.37% |
| 2022 | −63.73% |
| 2021 (partial year) | −50.28% |
As of October 21, 2026.
KTTA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$20.43M | — |
| 2024 | $0.00 | −$13.90M | — |
| 2023 | $0.00 | −$15.96M | — |
| 2022 | $0.00 | −$13.94M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$20.86M | −$20.43M | — |
| 2024 | $0.00 | — | −$14.25M | −$13.90M | — |
| 2023 | $0.00 | — | −$15.98M | −$15.96M | — |
| 2022 | $0.00 | $373.36K | −$12.59M | −$13.94M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
YahooPasithea Sets November Debut For Early PAS-004 Clinical Trial Results
BenzingaPasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B